Radioligand Therapy Global Market Report 2025

Description

Radioligand therapy (RLT) is an advanced targeted cancer treatment that attaches a radioactive isotope to a ligand specifically designed to bind to cancer cell receptors. Once administered, it targets tumor cells and delivers precise radiation directly to them, minimizing damage to healthy tissues. This targeted mechanism helps reduce side effects and enhances treatment outcomes, particularly in cases resistant to conventional therapies.

The primary types of radioligands used in RLT include alpha emitters, beta emitters, Auger emitters, and combined emission radioligands. Alpha emitters release high-energy alpha particles over very short distances, typically a few cell layers, making them highly effective for precise cell destruction. These radioligands are engineered to bind to specific molecular targets, such as hormone receptors, growth factor receptors, tumor antigen markers, and others. They can be administered via multiple routes, including intravenous (IV), intramuscular (IM), subcutaneous, and oral. Radioligand therapy is applied in treating a variety of conditions, including oncological and cardiovascular disorders, neurological diseases, and infectious diseases, and is utilized across hospitals, diagnostic laboratories, research institutions, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The radioligand therapy market research report is one of a series of new reports from The Business Research Company that provides radioligand therapy market statistics, including the radioligand therapy industry global market size, regional shares, competitors with the radioligand therapy market share, detailed radioligand therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the Radioligand therapy industry. This radioligand therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.01 billion in 2024 to $6.64 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to the increasing use of liquid biopsies, the emergence of tumor-agnostic therapies, the integration of artificial intelligence in oncology, the expanding pipeline of bispecific antibodies, and the rise in government funding for cancer research.

The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $9.77 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing investments by major pharmaceutical companies in oncology startups, greater utilization of real-world evidence, expansion of research in radiopharmaceuticals and theranostics, strengthened collaborations between academia and industry, and the rising prevalence of rare and orphan cancers. Key trends expected during this period include AI-driven design of radiopharmaceuticals, theranostics with combined imaging and therapy platforms, microfluidics-based radiotracer synthesis, development of next-generation alpha-emitting isotopes, and 3D-printed personalized dosimetry devices.

The rising incidence of cancer is expected to drive growth in the radioligand therapy market in the coming years. Cancer is characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread throughout the body. The increase in cancer cases is linked to long-term exposure to environmental pollutants that damage DNA, disrupt cellular function, and promote abnormal cell proliferation. Radioligand therapy addresses cancer by delivering targeted radiation to tumor cells via ligands that bind to specific receptors, minimizing damage to healthy tissues while destroying cancer cells internally. For example, in January 2022, the American Cancer Society, a U.S.-based non-profit organization, reported that approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were expected in the U.S., translating to roughly 1,670 deaths per day. Therefore, the growing prevalence of cancer is supporting the expansion of the radioligand therapy market.

Companies in the radioligand therapy market are increasingly focusing on the development of advanced facilities to improve production efficiency while ensuring consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. Radioligand therapy facilities are specialized centers equipped to handle and deliver radioactive drugs for targeted cancer therapy, employing advanced imaging systems and radiation shielding, along with trained personnel and strict safety protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana, which received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, featuring fully automated production lines designed for efficient, time-sensitive manufacturing to meet rising patient demand in the U.S. and Canada.

In December 2023, Eli Lilly and Company, a U.S.-based pharmaceutical firm, acquired POINT Biopharma Global Inc. for \$1.4 billion. This acquisition strengthens Eli Lilly's oncology portfolio by integrating advanced radioligand therapy capabilities to enhance precision cancer treatment options. POINT Biopharma Global Inc., also based in the U.S., specializes in the development of radioligand therapies for cancer.

Major players in the radioligand therapy market are Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc., OncoSil Medical Ltd.

North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in radioligand therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the radioligand therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radioligand Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on radioligand therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radioligand therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radioligand therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type Of Radioligand: Alpha Emitters; Beta Emitters; Auger Emitters; Combined Emissions
2) By Molecular Target: Hormone Receptors; Growth Factor Receptors; Antigen Tumor Markers; Other Molecular Targets
3) By Route Of Administration: Intravenous (IV); Intramuscular (IM); Subcutaneous; Oral
4) By Application: Oncology; Cardiovascular Disorders; Neurological Disorders; Infectious Diseases
5) By End-User: Hospitals; Diagnostic Laboratories; Research Institutions; Home Care Settings
Subsegments:
1) By Alpha Emitters: Actinium-225 (Ac-225); Radium-223 (Ra-223); Astatine-211 (At-211); Bismuth-213 (Bi-213)
2) By Beta Emitters: Lutetium-177 (Lu-177); Iodine-131 (I-131); Yttrium-90 (Y-90); Samarium-153 (Sm-153)
3) By Auger Emitters: Iodine-125 (I-125); Indium-111 (In-111); Gallium-67 (Ga-67); Thallium-201 (Tl-201)
4) By Combined Emissions: Terbium-161 (Tb-161); Copper-67 (Cu-67); Rhenium-186 (Re-186); Lead-212 (Pb-212)
Companies Mentioned: Bayer AG; Novartis AG; Eli Lilly and Company; Lantheus Holdings Inc.; Curium LLC; Eckert & Ziegler Strahlen- und Medizintechnik AG; Molecular Partners AG; Telix Pharmaceuticals; Nanobiotix S.A.; Mariana Oncology Inc.; Artios Pharma Limited; AdvanCell Pty Ltd.; Evergreen Theragnostics Inc.; Fusion Pharmaceuticals Inc.; RadioMedix Inc.; Ariceum Therapeutics GmbH; Radiopharm Theranostics Limited; Convergent Therapeutics Inc.; C-Ray Therapeutics Inc.; OncoSil Medical Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37874

1. Executive Summary

2. Radioligand Therapy Market Characteristics

3. Radioligand Therapy Market Trends And Strategies

4. Radioligand Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Radioligand Therapy Growth Analysis And Strategic Analysis Framework

5.1. Global Radioligand Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Radioligand Therapy Market Growth Rate Analysis
5.4. Global Radioligand Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Radioligand Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Radioligand Therapy Total Addressable Market (TAM)

6. Radioligand Therapy Market Segmentation

6.1. Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alpha Emitters
Beta Emitters
Auger Emitters
Combined Emissions
6.2. Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hormone Receptors
Growth Factor Receptors
Antigen Tumor Markers
Other Molecular Targets
6.3. Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous (IV)
Intramuscular (IM)
Subcutaneous
Oral
6.4. Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Cardiovascular Disorders
Neurological Disorders
Infectious Diseases
6.5. Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Diagnostic Laboratories
Research Institutions
Home Care Settings
6.6. Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Actinium-225 (Ac-225)
Radium-223 (Ra-223)
Astatine-211 (At-211)
Bismuth-213 (Bi-213)
6.7. Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lutetium-177 (Lu-177)
Iodine-131 (I-131)
Yttrium-90 (Y-90)
Samarium-153 (Sm-153)
6.8. Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Iodine-125 (I-125)
Indium-111 (In-111)
Gallium-67 (Ga-67)
Thallium-201 (Tl-201)
6.9. Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Terbium-161 (Tb-161)
Copper-67 (Cu-67)
Rhenium-186 (Re-186)
Lead-212 (Pb-212)

7. Radioligand Therapy Market Regional And Country Analysis

7.1. Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Radioligand Therapy Market

8.1. Asia-Pacific Radioligand Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Radioligand Therapy Market

9.1. China Radioligand Therapy Market Overview
9.2. China Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Radioligand Therapy Market

10.1. India Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Radioligand Therapy Market

11.1. Japan Radioligand Therapy Market Overview
11.2. Japan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Radioligand Therapy Market

12.1. Australia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Radioligand Therapy Market

13.1. Indonesia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Radioligand Therapy Market

14.1. South Korea Radioligand Therapy Market Overview
14.2. South Korea Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Radioligand Therapy Market

15.1. Western Europe Radioligand Therapy Market Overview
15.2. Western Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Radioligand Therapy Market

16.1. UK Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Radioligand Therapy Market

17.1. Germany Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Radioligand Therapy Market

18.1. France Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Radioligand Therapy Market

19.1. Italy Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Radioligand Therapy Market

20.1. Spain Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Radioligand Therapy Market

21.1. Eastern Europe Radioligand Therapy Market Overview
21.2. Eastern Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Radioligand Therapy Market

22.1. Russia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Radioligand Therapy Market

23.1. North America Radioligand Therapy Market Overview
23.2. North America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Radioligand Therapy Market

24.1. USA Radioligand Therapy Market Overview
24.2. USA Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Radioligand Therapy Market

25.1. Canada Radioligand Therapy Market Overview
25.2. Canada Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Radioligand Therapy Market

26.1. South America Radioligand Therapy Market Overview
26.2. South America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Radioligand Therapy Market

27.1. Brazil Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Radioligand Therapy Market

28.1. Middle East Radioligand Therapy Market Overview
28.2. Middle East Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Radioligand Therapy Market

29.1. Africa Radioligand Therapy Market Overview
29.2. Africa Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Radioligand Therapy Market Competitive Landscape And Company Profiles

30.1. Radioligand Therapy Market Competitive Landscape
30.2. Radioligand Therapy Market Company Profiles
- 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Curium LLC Overview, Products and Services, Strategy and Financial Analysis

31. Radioligand Therapy Market Other Major And Innovative Companies

31.1. Eckert & Ziegler Strahlen- und Medizintechnik AG
31.2. Molecular Partners AG
31.3. Telix Pharmaceuticals
31.4. Nanobiotix S.A.
31.5. Mariana Oncology Inc.
31.6. Artios Pharma Limited
31.7. AdvanCell Pty Ltd.
31.8. Evergreen Theragnostics Inc.
31.9. Fusion Pharmaceuticals Inc.
31.10. RadioMedix Inc.
31.11. Ariceum Therapeutics GmbH
31.12. Radiopharm Theranostics Limited
31.13. Convergent Therapeutics Inc.
31.14. C-Ray Therapeutics Inc.
31.15. OncoSil Medical Ltd.

32. Global Radioligand Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Radioligand Therapy Market

34. Recent Developments In The Radioligand Therapy Market

35. Radioligand Therapy Market High Potential Countries, Segments and Strategies

35.1 Radioligand Therapy Market In 2029 - Countries Offering Most New Opportunities
35.2 Radioligand Therapy Market In 2029 - Segments Offering Most New Opportunities
35.3 Radioligand Therapy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer